Search Results | Showing 21 - 30 of 119 results for "Pharmaceuticals" |
| | | ... are companies on the ASX with interesting growth prospects in global markets, he said. Some examples are Felix Pharmaceuticals and Immutep, which have an innovative approach to detecting and treating cancer, and Janison, which conducts assessments and ... |
| | | | ... where she is directing its rebranding and operations with a focus on sustainability and also a director at TauRx Pharmaceuticals. She is actively involved in the evaluation, acquisition and planning of seaport terminal real estate, the development of ... |
| | | | ... the boards of Sydney Living Museums, Australian Institute of Company Directors, Knight Frank Australia, Holmart Pharmaceuticals and Murray River Organics. Rutherford was one of the founders of Koda Capital and was chief financial officer and chief operating ... |
| | | | ... industry is also seen to be a major casualty, as components face up to 10% tariffs after Brexit. Medicines and pharmaceuticals could face delays too for obtaining treatment for patients. All these sectors will also have deal with a weaker sterling." ... |
| | | | ... Fund VI, which has $2.5 billion and the Secure Assets Fund, which has $360 million. Its investments include iNova Pharmaceuticals, Patties Foods, Evolution Healthcare and LifeHealthcare. |
| | | | ... received $37.7 million in realised pay. He was followed by CSL's Paul Perreault at $30.5 million, Clinuvel Pharmaceuticals chief Philippe Wolgen at $20.6 million and Treasury Wine Estates chief Michael Clarke at $19.8 million. "Boards of ASX200 companies ... |
| | | | ... services, hotels, cafes and restaurants, recreation and culture. Spending on goods rose, most notably in food and pharmaceuticals, as households prepared for the introduction of restrictions. The ABS said trade also took a hit, unsurprisingly as borders ... |
| | | | ... dividends. Sectors with relatively low risk of reducing dividends are food retailers, telecommunication companies, pharmaceuticals, agriculture, technology, regulated utilities, iron ore and gold producers. |
| | | | ... McCann has chaired the boards of Macquarie Group, Origin Energy, Healthscope and Citadel. He currently chairs Telix Pharmaceuticals. He worked as a commercial lawyer from 1970 to 2004 as a partner at Allens Arthur Robinson. "I am very pleased that a ... |
| | | | ... backed by a group of private investors based in China. Led by An LuFan, executive director of Chinese-based D&R Pharmaceuticals the fund will focus on drug development and clinical diagnostics. Dr Stephen Rodda from the University of Adelaide and Dr ... |
|